OTC Markets OTCPK - Delayed Quote USD

Propanc Biopharma, Inc. (PPCB)

6.46

+0.96

+(17.45%)

At close: April 23 at 4:00:00 PM EDT

Propanc Biopharma’s Peer Reviewed Articles for Proenzymes Cancer Treatment Generates "Unprecedented" Interest

MELBOURNE, Australia, August 21, 2024--Two scientific journal articles published by the Company and its research partners reached 10 citations and 4,500 reads, respectively, in August, 2024

Business Wire 7 months ago

PPCB
+17.45%
Propanc Biopharma Receives Notice of Allowance for "Proenzyme Composition" Patent in North America

MELBOURNE, Australia, August 14, 2024--The proenzymes composition patent is an important part of the IP portfolio covering possible future clinical dosage ranges for PRP

Business Wire 8 months ago

PPCB
+17.45%
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid Tumors

MELBOURNE, Australia, July 17, 2024--"The implication is that PRP will enable PD-L1 non responders to become responders," according to Dr Julian Kenyon, MD, MB, ChB

Business Wire 9 months ago

PPCB
+17.45%
Propanc Biopharma Receives Certificate of Grant for "Proenzymes Composition" Patent from Japanese Patent Office

MELBOURNE, Australia, June 25, 2024--We are building an extensive and mature intellectual property portfolio around the use of proenzymes as a novel treatment for advanced solid tumors

Business Wire 9 months ago

PPCB
+17.45%

Performance Overview

Return	PPCB	S&P 500 (^GSPC)
YTD	+1,614,900.00%	-8.60%
1-Year	+269,066.65%	+6.02%
3-Year	-71.42%	+25.85%